H.C. Wainwright analyst Robert Burns raised the firm’s price target on Nurix Therapeutics (NRIX) to $31 from $28 and keeps a Buy rating on the shares. The firm says the updated data for bexobrutideg potentially de-risks the confirmatory trial.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Balanced Outlook on Nurix Therapeutics: Promising Developments Amid Uncertainties
- Nurix Therapeutics price target raised to $30 from $27 at BTIG
- Nurix Therapeutics Reports Promising Data at Hematology Meeting
- Nurix Therapeutics presents data from Phase 1 trial of bexobrutideg
- Nurix presents new clinical data from Phase 1a/1b NX-5948-301 study